CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or the "Company") today released a letter to shareholders from the Chairman of the Company's Board ...

CytoMed has generated the critical cell banks for the iPSC-derived hybrid of gamma delta T and Natural Killer cell technology and is currently undergoing process development into a potentially very ...

Fate Therapeutics uses iPSC and gene editing to offer scalable off-the-shelf therapies. Read more to see why I rate FATE ...

About Fate Therapeutics, Inc. Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to bringing a ...

Embryonic stem cells and induced pluripotent stem cells are pluripotent stem cells. Optimized lentiviral transduction enhances gene delivery in human iPSC-derived lung organoids, enabling advanced ...

STEM Potential supports you through years 10 and 12 with insightful lectures, subject-specific workshops and a non-residential summer school. STEM Potential is a multi-year programme of activities and ...

An investigator-initiated Phase 1/2 trial of CNTY-101, an investigational therapy, has been announced for the treatment of B-cell mediated autoimmune diseases, including systemic lupus erythematosus ...

Noise-induced hearing loss can be temporary or permanent ... they can do so with a strong enough force to shear off the tiny hairs and other cells that line the ear. These hairs move as sound ...

This review summarized three groundbreaking approaches: islet organoids differentiated from Procr+ pancreatic progenitor cells, chemically induced pluripotent stem cells (CiPSCs), and endoderm stem ...

The therapeutic candidate (CAR-NK cell therapy) comprises allogeneic induced pluripotent stem cells (iPSC)-derived natural killer cells which are genetically engineered to express chimeric antigen ...

Scientists thereby presume that cancer stem cells (CSCs ... the undifferentiated and self-renewing state of cancer cells and inhibition of the HA-HIF-1 axis similarly reduces the CSC-like ...

Established guidelines for the management of chemotherapy-induced nausea and vomiting (CINV) currently recommend three main classes of drugs: 5-HT 3 receptor antagonists, NK 1 receptor antagonists ...